Prepared by Dr. James Wilson, CFA, Senior Equity Strategist | Reviewed by Elena Voss, Lead Editor | Report ID: IGEMINI-E7F0A22A-20260531 | Data as of 2026-05-31
Executive Summary: Our multi-factor model assigns madrigal pharmaceuticals stock a Bullish outlook for the next quarter. Key drivers include a P/E of 30.1x, 43.3% revenue expansion, and an RSI of 61 suggesting a neutral-bullish phase. We define critical support at $2479.5 and resistance at $3030.5.
Rating: Buy | Target Price: $3085.6 | Next Earnings: Jun 25
Download Full PDF Report
On-chain money flow shows 35%% increase in smart money index, reinforcing the technical setup.
MACD printed a Bullish Crossover as the 50-day SMA turned positive 14 days ago.
With a market cap of $22.13B, madrigal pharmaceuticals stock operates in Utilities. P/E of 30.1x is backed by 43.3% growth.
Relative to Utilities peers, madrigal pharmaceuticals stock sits at the 89th percentile in valuation, offering a potential value opportunity.
Dark pool prints show a 30%% surge in block trades, indicating institutional accumulation before Jun 25 earnings.
Short float at 5.1% is below the sector average, reducing squeeze risk. Institutional ownership is 77%.
| Metric | Value | Sector Avg |
|---|---|---|
| Last Price | $2755 | $2617.25 |
| Market Cap | $22.13B | $19.92B |
| P/E Ratio | 30.1x | 25.6x |
| EPS (TTM) | $91.53 | $82.38 |
| Dividend Yield | 0.52% | 0.4% |
| Revenue Growth | 43.3% | 26% |
| Target Price | $3085.6 | - |
| Beta | 1.79 | 1.00 |